TREATMENT OF CASTLEMAN DISEASE
Provided are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of CXCL13. Also disclosed are methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of CXCL13 or of CXCR5. Also provided herein are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of specified biomarkers. The present disclosure also provides methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of the JAK-STAT3 pathway. Also disclosed are methods for assessing the absence or presence of iMCD in a subject..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 04. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
FAJGENBAUM DAVID C [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-04, Last update posted on www.tib.eu: 2024-01-30, Last updated: 2024-02-02 |
|---|
| Patentnummer: |
US2024002520 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019049285 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019049285 | ||
| 003 | DE-627 | ||
| 005 | 20240202090334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019049285 | ||
| 035 | |a (EPA)US2024002520 | ||
| 035 | |a (EPA)81601793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a FAJGENBAUM DAVID C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TREATMENT OF CASTLEMAN DISEASE |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-04, Last update posted on www.tib.eu: 2024-01-30, Last updated: 2024-02-02 | ||
| 520 | |a Provided are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of CXCL13. Also disclosed are methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of CXCL13 or of CXCR5. Also provided herein are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of specified biomarkers. The present disclosure also provides methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of the JAK-STAT3 pathway. Also disclosed are methods for assessing the absence or presence of iMCD in a subject. | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 04. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81601793/publication/US2024002520A1?q=US2024002520 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2024 |b 04 |c 01 |
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 01 | ||